<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04038359</url>
  </required_header>
  <id_info>
    <org_study_id>VS-0145-229</org_study_id>
    <nct_id>NCT04038359</nct_id>
  </id_info>
  <brief_title>A Phase 2 Study Comparing 2 Intermittent Dosing Schedules of Duvelisib in Subjects With Indolent Non-Hodgkin Lymphoma. (TEMPO)</brief_title>
  <official_title>A Phase 2, Randomized, Open-label, 2-Arm Study Comparing 2 Intermittent Dosing Schedules of Duvelisib in Subjects With Indolent Non Hodgkin Lymphoma (iNHL) (TEMPO)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>SecuraBio</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>SecuraBio</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will examine the effects of predefined 2 week duvelisib dose holidays on tumor&#xD;
      responses and safety/tolerability.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase 2, randomized, open-label, 2 arm study designed to evaluate the efficacy and&#xD;
      safety of prescribed drug holidays of duvelisib treatment in subjects with R/R iNHL who have&#xD;
      received at least 1 prior systemic therapy.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">September 24, 2019</start_date>
  <completion_date type="Anticipated">July 29, 2024</completion_date>
  <primary_completion_date type="Anticipated">May 30, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>ORR (Objective Response Rate)</measure>
    <time_frame>36 months</time_frame>
    <description>Proportion of subjects achieving a CR or PR will be estimated as per IWG Criteria.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>PFS (Progression Free Survival)</measure>
    <time_frame>5 years</time_frame>
    <description>From time of first dose of study intervention to PD or death.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ORR (Objective Response Rate)</measure>
    <time_frame>ORR estimated at 6, 12, 18, and 24 months after first dose of study intervention.</time_frame>
    <description>Proportion of subjects achieving a CR or PR will be estimated as per Lugano Criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DOR (Duration of Response)</measure>
    <time_frame>5 years</time_frame>
    <description>From the time of first response to PD using KM methods.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>OS (Overall Survival)</measure>
    <time_frame>5 years</time_frame>
    <description>From time of first dose of study intervention to death.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>LNRR (Lymph Node Response Rate)</measure>
    <time_frame>36 months</time_frame>
    <description>LNRR will be calculated as the proportion of subjects achieving ≥ 50% decrease in the SPD of target lymph nodes.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TTFR (Time To First Relapse)</measure>
    <time_frame>36 months</time_frame>
    <description>From the time of first dose of study intervention to time of first CR or PR.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with treatment-emergent adverse events as assessed by CTCAE v5.0</measure>
    <time_frame>36 months</time_frame>
    <description>From the time of screening to the end of Safety Follow-Up period of the study.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peak Plasma Concentration (Cmax)</measure>
    <time_frame>36 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TTF (Time To Treatment Failure)</measure>
    <time_frame>5 years</time_frame>
    <description>From first dose of study intervention until discontinuation for any reason and will be summarized using KM methods.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the plasma concentration versus time curve (AUC)</measure>
    <time_frame>36 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">102</enrollment>
  <condition>Indolent Non-hodgkin Lymphoma</condition>
  <arm_group>
    <arm_group_label>Duvelisib, Continuous and Intermittent Dosing</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Duvelisib 25 mg BID continuously for 10 weeks, followed by 25 mg BID dosed two weeks on and two weeks off of each subsequent 4-week cycles.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Duvelisib, Intermittent Dosing</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Duvelisib 25 mg BID dosed two weeks on and two weeks off.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Duvelisib</intervention_name>
    <description>PI3K Inhibitor</description>
    <arm_group_label>Duvelisib, Continuous and Intermittent Dosing</arm_group_label>
    <arm_group_label>Duvelisib, Intermittent Dosing</arm_group_label>
    <other_name>Copiktra, VS-0145</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age ≥ 18 years, ECOG performance status ≤ 2&#xD;
&#xD;
          -  Histologically confirmed diagnosis of iNHL (Subtypes include FL Grades 1 to 3a,&#xD;
             marginal zone lymphoma (splenic, nodal, or extranodal), or SLL&#xD;
&#xD;
          -  Must have received 1 prior systemic regimen for iNHL&#xD;
&#xD;
          -  Must have documented radiologic evidence of disease progression, and at least 1&#xD;
             bi-dimensionally measurable lesion ≥ 1.5 cm (which has not been previously&#xD;
             irradiated), according to 2007 revised IWG criteria&#xD;
&#xD;
          -  Must have adequate organ function defined by the following laboratory parameters:&#xD;
&#xD;
               -  Absolute neutrophil count (ANC) ≥ 1.0 × 10^9/L&#xD;
&#xD;
               -  Platelet count ≥ 75 × 10^9/L&#xD;
&#xD;
               -  Serum creatinine &lt; 2.0 mg/dL (197 µmol/L)&#xD;
&#xD;
               -  Total bilirubin ≤ 1.5 × upper limit of normal (ULN) (exception: subjects with&#xD;
                  Gilbert's Syndrome may have a bilirubin &gt; 1.5 × ULN)&#xD;
&#xD;
               -  Aspartate transaminase (AST)/serum glutamic-oxaloacetic transaminase (SGOT) and&#xD;
                  alanine aminotransferase (ALT)/serum pyruvic transaminase (SGPT) ≤ 3.0 × ULN&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Anticancer treatment, major surgery, or use of any investigational drug within 28 days&#xD;
             before the start of study intervention; palliative radiation therapy is allowed if &gt; 7&#xD;
             days and any toxicity is Grade ≤ 1&#xD;
&#xD;
          -  Clinical or histological evidence of transformation to a more aggressive subtype of&#xD;
             lymphoma or grade 3b FL or Richters' transformation or CLL&#xD;
&#xD;
          -  Prior allogeneic hematopoietic stem cell transplant (HSCT); treatment with a PI3K&#xD;
             inhibitor&#xD;
&#xD;
          -  History of drug-induced colitis or pneumonitis; TB treatment ≤ 2 years prior to&#xD;
             randomization; administration of a live or live attenuated vaccine within 6 weeks of&#xD;
             randomization&#xD;
&#xD;
          -  Ongoing treatment with chronic immunosuppressants or systemic steroids or treatment&#xD;
             for systemic bacterial, fungal, or viral infection&#xD;
&#xD;
          -  Active cytomegalovirus (CMV) or Epstein-Barr virus (EBV) infection&#xD;
&#xD;
          -  Unable to receive prophylactic treatment for pneumocystis, herpes simplex virus (HSV),&#xD;
             or herpes zoster (VZV) at screening&#xD;
&#xD;
          -  Concurrent administration of medications or foods that are strong inhibitors or&#xD;
             inducers of cytochrome P450 3A (CYP3A). No prior use within 2 weeks before the start&#xD;
             of study intervention.&#xD;
&#xD;
          -  Baseline QTcF &gt; 500 ms&#xD;
&#xD;
          -  Concurrent active malignancy other than non-melanoma skin cancer or carcinoma in situ&#xD;
             of the cervix, bladder cancer, or prostate cancer not requiring treatment. Subjects&#xD;
             with previous malignancies are eligible if they have been disease-free for 2 years or&#xD;
             more.&#xD;
&#xD;
          -  Unstable or severe uncontrolled medical condition that would, in the Investigator's&#xD;
             judgment, increase the subject's risk to participating in this study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Cohan, MD</last_name>
    <role>Study Director</role>
    <affiliation>SecuraBio Chief Medical Officer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>George Washington University</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20052</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Florida Cancer Specialists - Fort Myers</name>
      <address>
        <city>Fort Myers</city>
        <state>Florida</state>
        <zip>33901</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Florida Cancer Specialists $ Research Institute - Lecanto</name>
      <address>
        <city>Lecanto</city>
        <state>Florida</state>
        <zip>34461</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mid-Florida Cancer Centers</name>
      <address>
        <city>Orange City</city>
        <state>Florida</state>
        <zip>32763</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Florida Cancer Specialists - Panhandle</name>
      <address>
        <city>Tallahassee</city>
        <state>Florida</state>
        <zip>32308</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Florida Cancer Specialists - West Palm Beach</name>
      <address>
        <city>West Palm Beach</city>
        <state>Florida</state>
        <zip>33401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Robert H. Lurie Comprehensive Cancer Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Agnes Cancer Institute</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Medical Center</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64132</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nebraska Cancer Specialists</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Comprehensive Cancer Centers of Nevada</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89169</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novant Health Cancer Specialists - Charlotte</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Greenville Health System Cancer Institute</name>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <zip>29615</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tennessee Oncology</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baylor Scott and White Research Institute - Hematology/Oncology</name>
      <address>
        <city>Temple</city>
        <state>Texas</state>
        <zip>76508</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>FN Hradec Kralove</name>
      <address>
        <city>Hradec Králové</city>
        <zip>500 05</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fakultni nemocnice Ostrava</name>
      <address>
        <city>Ostrava - Poruba</city>
        <zip>708 52</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vseobecna fakultni nemocnice v Praze</name>
      <address>
        <city>Praha 2</city>
        <zip>128 08</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Evangelisches Klinikum Bethel</name>
      <address>
        <city>Bielefeld</city>
        <zip>33611</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IRCCS IRST - Oncology</name>
      <address>
        <city>Meldola</city>
        <state>Forli</state>
        <zip>47014</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>A.O.di Bologna Policl.S.Orsola</name>
      <address>
        <city>Bologna</city>
        <zip>40138</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale San Raffaele</name>
      <address>
        <city>Milano</city>
        <zip>20132</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ieo, Irccs</name>
      <address>
        <city>Milano</city>
        <zip>20141</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Santa Maria di Terni</name>
      <address>
        <city>Terni</city>
        <zip>05100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale di Circolo, PO Varese, AO Ospedale di Circolo e Fon</name>
      <address>
        <city>Varese</city>
        <zip>21100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seoul National University Bundang Hospital</name>
      <address>
        <city>Seongnam-si</city>
        <zip>13620</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>03080</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Severance Hospital, Yonsei University Health System</name>
      <address>
        <city>Seoul</city>
        <zip>03722</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Asan Medical Center - Oncology</name>
      <address>
        <city>Seoul</city>
        <zip>05505</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Samsung Medical Center - Hematology-Oncology</name>
      <address>
        <city>Seoul</city>
        <zip>06351</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Catholic University of Korea, Seoul St. Mary's Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>06591</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Korea University Guro Hospital - Medical Oncology</name>
      <address>
        <city>Seoul</city>
        <zip>08308</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wojewódzki Szpital Specjalistyczny sp.z o.o.</name>
      <address>
        <city>Slupsk</city>
        <state>Pomorskie</state>
        <zip>76-200</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Silesian Healthy Blood Clinic</name>
      <address>
        <city>Chorzów</city>
        <zip>41-500</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gabinety Lekarskie Hema</name>
      <address>
        <city>Lublin</city>
        <zip>20-601</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Examen Sp. z o.o.</name>
      <address>
        <city>Skórzewo</city>
        <zip>60-185</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>City Clinical Hospital n.a. Botkin</name>
      <address>
        <city>Moscow</city>
        <zip>125284</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Leningrad Regional Clinical Hospital</name>
      <address>
        <city>Sankt-Peterburg</city>
        <zip>194291</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cruk Clinical Trials Unit</name>
      <address>
        <city>Glasgow</city>
        <zip>G12 0YN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Christie Hospital NHS Foundation Trust</name>
      <address>
        <city>Manchester</city>
        <zip>M20 4BX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Czechia</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Korea, Republic of</country>
    <country>Poland</country>
    <country>Russian Federation</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>July 10, 2019</study_first_submitted>
  <study_first_submitted_qc>July 26, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 30, 2019</study_first_posted>
  <last_update_submitted>May 17, 2021</last_update_submitted>
  <last_update_submitted_qc>May 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>PI3K Inhibitor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

